Blue Matter Blog

Finding Patients: A Key Challenge in Rare Diseases
May 30, 2018

Part 2 in a Series on Rare Diseases Part 1 of this series provided an overview of rare diseases and the special challenges they present to biopharmaceutical companies.  In this installment, we explore one of the most basic—and most confounding—of those challenges:  Finding patients. In the European Union, a disease is considered rare when it …

Blue Matter Academy: Investing in Learning
May 25, 2018

Blue Matter Academy (BMA) is Blue Matter Consulting’s in-house learning and development organization.  Officially launched in 2017, BMA’s goal is to provide ongoing learning opportunities for all Blue Matter team members.  Recently, Karen Foster, Learning Strategist and Head of Blue Matter Academy, took the time to answer some common questions about the Academy and Blue …

9th European Conference on Rare Diseases and Orphan Products
ECRD Vienna 2018 Recap
May 15, 2018

Recently (10-12 May), we traveled to Vienna to attend the 9th European Conference on Rare Diseases and Orphan Products (ECRD).  In this article, we describe some of the key takeaways from the conference, and the major implications for biopharmaceutical companies operating in this space. Our Focus on Rare Diseases More than 7,000 diseases are classified …